Nanotechnology-Based Topical Treatments For Androgenic Alopecia

The document discusses the potential of nanotechnology-based topical treatments for androgenic alopecia, a common form of hair loss influenced by hormonal factors, particularly dihydrotestosterone (DHT). Current treatments like oral finasteride and dutasteride, which inhibit DHT production, have significant side effects, while topical minoxidil has limitations in efficacy and formulation. Nanocarriers, such as polymeric nanoparticles and liposomes, offer a promising approach by enhancing drug delivery and targeting hair follicles more effectively. However, challenges remain in optimizing nanocarrier size and composition for effective follicular targeting. The document emphasizes the need for standardized experimental models, particularly using porcine skin, to improve the reliability of in vitro tests. The future of androgenic alopecia treatment lies in further developing nanotechnology to safely and effectively deliver a combination of drugs with different mechanisms of action.